Bacteria Resistant to Tigecycline Monotherapy
Tigecycline, a glycylcycline antibiotic, shows broad-spectrum activity against many Gram-positive, Gram-negative, and anaerobic bacteria but has limited efficacy against certain species when used alone. Key resistant species include Proteus spp. (e.g., Proteus mirabilis, Proteus vulgaris) and Providencia spp. (e.g., Providencia stuartii, Providencia rettgeri), due to intrinsic resistance from mechanisms like efflux pumps and poor accumulation in these Enterobacterales.[1][2]
Why These Species Resist Tigecycline Alone
These bacteria lack porins needed for tigecycline uptake and overexpress efflux systems (e.g., AcrAB-TolC), reducing intracellular drug levels below MIC thresholds (often >8-16 µg/mL). In vitro data confirm MIC90 >16 µg/mL for Proteus and Providencia, exceeding susceptible breakpoints (≤2 µg/mL per CLSI/EUCAST).[3][4] Pseudomonas aeruginosa and many Burkholderia strains also resist intrinsically, with MICs >32 µg/mL, due to similar efflux and outer membrane barriers.[1]
Common Pathogens Where Tigecycline Fails Solo
- Pseudomonas aeruginosa: High-level resistance; tigecycline does not penetrate well, and clinical failure rates exceed 50% in monotherapy for infections like VAP.[2][5]
- Stenotrophomonas maltophilia: Efflux-mediated; rarely susceptible (MIC90 >32 µg/mL).[3]
- Burkholderia cepacia complex: Intrinsic resistance limits use in cystic fibrosis patients.[4]
Acinetobacter baumannii can develop resistance during therapy, but many strains remain susceptible initially (MIC ≤2 µg/mL).[1]
Clinical Scenarios with High Resistance Risk
Monotherapy fails most often in polymicrobial infections or those involving biofilms (e.g., Proteus in UTIs, Pseudomonas in pneumonia). Guidelines (IDSA) recommend combinations like tigecycline + colistin/meropenem for CRAB or MDR Pseudomonas, as solo tigecycline yields poor outcomes in bacteremia or ventilator-associated infections.[5][6] No FDA approval for monotherapy in confirmed Proteus/Providencia cases.
Comparison to Other Tetracyclines
Unlike doxycycline or minocycline (active against some Proteus), tigecycline's bulkier structure worsens uptake issues in these species. Minocycline covers more Stenotrophomonas but not Pseudomonas.[2][3]
[1]: FDA Tigecycline Label
[2]: Clinical Infectious Diseases - Tigecycline Review (2009)
[3]: EUCAST Breakpoints
[4]: Antimicrobial Agents and Chemotherapy - Tigecycline MIC Data (2005)
[5]: IDSA HAP/VAP Guidelines (2016)
[6]: CLSI M100 (2023)